Song J, Wei R, Liu C, Zhao Z, Liu X, Wang Y
Nat Commun. 2025; 16(1):2175.
PMID: 40038297
PMC: 11880398.
DOI: 10.1038/s41467-025-57465-7.
Zhang J, Wang G, Liu J, Tang F, Wang S, Li Y
Front Oncol. 2025; 15:1513622.
PMID: 40012546
PMC: 11860100.
DOI: 10.3389/fonc.2025.1513622.
Jiang Y, Liao C, Lai J, Peng Y, Chen Q, Zheng X
Sci Rep. 2025; 15(1):6951.
PMID: 40011455
PMC: 11865440.
DOI: 10.1038/s41598-024-84129-1.
Dai L, Lou N, Huang L, Li L, Tang L, Shi Y
Cancer Immunol Immunother. 2025; 74(4):123.
PMID: 39998673
PMC: 11861843.
DOI: 10.1007/s00262-025-03968-7.
Yao Y, Li B, Wang J, Chen C, Gao W, Li C
J Exp Clin Cancer Res. 2025; 44(1):62.
PMID: 39979981
PMC: 11841141.
DOI: 10.1186/s13046-025-03324-8.
Training and experimental validation a novel anoikis- and epithelial‒mesenchymal transition-related signature for evaluating prognosis and predicting immunotherapy efficacy in gastric cancer.
Zeng C, Xu C, Wei Y, Ma F, Wang Y
J Cancer. 2025; 16(4):1078-1100.
PMID: 39895782
PMC: 11786038.
DOI: 10.7150/jca.106029.
Myeloid cell-derived apCAFs promote HNSCC progression by regulating proportion of CD4 and CD8 T cells.
Ren F, Meng L, Zheng S, Cui J, Song S, Wang D
J Exp Clin Cancer Res. 2025; 44(1):33.
PMID: 39891284
PMC: 11783918.
DOI: 10.1186/s13046-025-03290-1.
Epigenetic Regulation of Stromal and Immune Cells and Therapeutic Targets in the Tumor Microenvironment.
Liu K, Li Y, Shen M, Xu W, Wu S, Yang X
Biomolecules. 2025; 15(1).
PMID: 39858465
PMC: 11764280.
DOI: 10.3390/biom15010071.
Deciphering mechanical cues in the microenvironment: from non-malignant settings to tumor progression.
Zhu Y, Chen J, Chen C, Tang R, Xu J, Shi S
Biomark Res. 2025; 13(1):11.
PMID: 39849659
PMC: 11755887.
DOI: 10.1186/s40364-025-00727-9.
Drug Delivery System Targeting Cancer-Associated Fibroblast for Improving Immunotherapy.
Zhang Z, Wang R, Chen L
Int J Nanomedicine. 2025; 20():483-503.
PMID: 39816375
PMC: 11734509.
DOI: 10.2147/IJN.S500591.
Harnessing the tumor microenvironment: targeted cancer therapies through modulation of epithelial-mesenchymal transition.
Glaviano A, Lau H, Carter L, Lee E, Lam H, Okina E
J Hematol Oncol. 2025; 18(1):6.
PMID: 39806516
PMC: 11733683.
DOI: 10.1186/s13045-024-01634-6.
Prognostic implications and therapeutic opportunities related to CAF subtypes in CMS4 colorectal cancer: insights from single-cell and bulk transcriptomics.
Ma M, Chu J, Zhuo C, Xiong X, Gu W, Li H
Apoptosis. 2025; .
PMID: 39755821
DOI: 10.1007/s10495-024-02063-z.
Unveiling immune cell response disparities in human primary cancer-associated fibroblasts between two- and three-dimensional cultures.
Yang J, Kulkarni N, Yamaji M, Shiraishi T, Pham T, Do H
PLoS One. 2024; 19(12):e0314227.
PMID: 39700125
PMC: 11658583.
DOI: 10.1371/journal.pone.0314227.
Wound healing: insights into autoimmunity, ageing, and cancer ecosystems through inflammation and IL-6 modulation.
Lacina L, Kolar M, Pfeiferova L, Gal P, Smetana Jr K
Front Immunol. 2024; 15:1403570.
PMID: 39676864
PMC: 11638159.
DOI: 10.3389/fimmu.2024.1403570.
Spatial analyses revealed CXCL5 and SLC6A14 as the markers of microvascular invasion in intrahepatic cholangiocarcinoma.
Fan G, Dai L, Xie T, Li L, Tang L, Han X
Hepatol Commun. 2024; 9(1).
PMID: 39670859
PMC: 11637745.
DOI: 10.1097/HC9.0000000000000597.
CXCR1 neutrophil infiltration orchestrates response to third-generation EGFR-TKI in EGFR mutant non-small-cell lung cancer.
Wang H, Xiong A, Chen X, Guo J, Tang Z, Wu C
Signal Transduct Target Ther. 2024; 9(1):342.
PMID: 39638994
PMC: 11621634.
DOI: 10.1038/s41392-024-02045-2.
Exosomal circular RNAs in tumor microenvironment: An emphasis on signaling pathways and clinical opportunities.
Li J, Zhou W, Wang H, Huang M, Deng H
MedComm (2020). 2024; 5(12):e70019.
PMID: 39584047
PMC: 11586091.
DOI: 10.1002/mco2.70019.
Mapping and tracing Grem1 stromal cells in an mouse utilizing cryopreserved intestinal sections prepared via modified Swiss-roll technique.
Jiang Y, Fu Z, Chen Y, Jin Q, Yang Y, Lin Z
iScience. 2024; 27(11):111173.
PMID: 39563897
PMC: 11574797.
DOI: 10.1016/j.isci.2024.111173.
Insulin-like growth factor 2 drives fibroblast-mediated tumor immunoevasion and confers resistance to immunotherapy.
Song D, Wu Y, Li J, Liu J, Yi Z, Wang X
J Clin Invest. 2024; 134(22).
PMID: 39545420
PMC: 11563680.
DOI: 10.1172/JCI183366.
Enhanced tumor control and survival in preclinical models with adoptive cell therapy preceded by low-dose radiotherapy.
Puebla-Osorio N, Fowlkes N, Barsoumian H, Xega K, Srivastava G, Kettlun-Leyton C
Front Oncol. 2024; 14:1407143.
PMID: 39445067
PMC: 11496962.
DOI: 10.3389/fonc.2024.1407143.